Molbio Diagnostics Seeks ₹200 Crore in IPO Amid Global Expansion

Molbio Diagnostics, a key player in the molecular diagnostics industry, is preparing for an initial public offering (IPO) aimed at raising ₹200 crore to bolster its capital expenditures. The company also plans to generate ₹740 crore through an offer for sale, which will reduce its promoter group’s stake from 46.6% to 43%.

Global Reach and Revenue Growth

Founded in 2000, Molbio Diagnostics operates six manufacturing sites across India and serves clients in over 90 countries. Its clientele includes government health agencies, diagnostic laboratories, hospitals, and international healthcare organizations. The company’s revenue has seen significant growth, largely driven by its tuberculosis diagnostic test kits, which account for a substantial portion of its sales.

The company reported a 31.5% annual increase in revenue from operations, reaching ₹1,445.7 crore, and a 40.2% rise in net profit to ₹164.1 crore between FY24 and FY26. During the same period, its EBITDA grew by 33.2% to ₹328.2 crore, with an EBITDA margin of 22.6% in FY26, up from 22% in FY24.

Product Portfolio and Market Potential

Molbio Diagnostics has developed the 'Truenat' platform, a portable diagnostic system designed to deliver accurate test results in under an hour, even in resource-limited settings. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays and extends its offerings through subsidiaries and strategic partnerships in areas like radiology and digital pathology.

Approximately 74% of the company’s revenue comes from selling test kits, with diagnostic kits for tuberculosis making up 70% of this segment. The dominance of a few key clients, contributing over half of the revenue, indicates a certain level of customer concentration risk.

Valuation and Investor Considerations

Post-IPO, Molbio Diagnostics is expected to demand a price-earnings (P/E) multiple of up to 57, positioning it among other healthcare diagnostics and medical device companies such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples ranging from 54 to 81.

While Molbio does not have directly comparable listed peers in India, its robust growth and strategic market positioning make it an attractive option for investors with a high-risk appetite seeking long-term growth potential. The company's expansion efforts and innovative product offerings could support sustained growth, though the high concentration of revenue from a limited number of clients remains a potential risk factor.